Rani Therapeutics Holdings, Inc. - 10-Q Summary (Period Ended June 30, 2026)
Business Context and Reporting Period
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing the RaniPill, a drug-agnostic oral delivery platform designed to administer biologics and drugs orally. The company operates in one segment and is headquartered in San Jose, California. This report covers the quarterly period ended June 30, 2026, and the six months ended June 30, 2026. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Contract Revenue | $3,416 | $172 |
| Total Operating Expenses | $20,583 | $22,690 |
| Net Loss | $(16,436) | $(23,962) |
| Net Loss Attributable to Rani Holdings | $(14,424) | $(13,956) |
| Cash, Cash Equivalents, and Marketable Securities | $53,391 | $49,709 |
| Net Cash Used in Operating Activities | $(15,523) | $(13,945) |
| Net Cash Provided by Financing Activities | $18,779 | $(3,543) |
Liquidity: As of June 30, 2026, the company held $4.9 million in cash and cash equivalents and $48.5 million in marketable securities. Management expects these funds to be sufficient to fund operations for at least twelve months from the filing date.
Material Changes vs. Prior Period
- Revenue Growth: Contract revenue increased significantly to $3.4 million for the six months ended June 30, 2026, compared to $0.2 million in the prior year period. This increase is primarily attributable to the Chugai Collaboration and License Agreement entered into in October 2025.
- Expense Reduction: Total operating expenses decreased by 9.3% to $20.6 million. Research and development expenses declined by 15.7% ($1.9 million) and general and administrative expenses declined by 2.0% ($0.2 million), driven largely by lower compensation costs.
- Net Loss Improvement: The consolidated net loss decreased by 31.4% to $16.4 million, primarily due to reduced operating expenses and a significant decrease in interest expense.
- Financing Activity: In May 2026, the company raised approximately $20.0 million in gross proceeds through a securities purchase agreement involving the issuance of Class A common stock and pre-funded warrants.
Guidance, Outlook, and Risks
- Clinical Progress: In July 2026 (subsequent to the period end), the company announced positive Phase 1a data for RT-114 (a GLP-1/GLP-2 agonist delivered via RaniPill HC), showing oral bioavailability exceeding 150% relative to subcutaneous injection. The Phase 1b study is expected to begin in 2026 with data anticipated in 2027.
- Collaborations: The company entered into a new R&D collaboration with PegBio Co., Ltd. in July 2026 to explore oral delivery of obesity and metabolic disease candidates. Existing collaborations with Chugai and ProGen remain active.
- Capital Needs: The company expects to continue incurring losses and will require substantial additional capital to complete clinical development, expand manufacturing, and commercialize products. Future funding may come from equity offerings, debt, or collaborations.
- Nasdaq Listing Risk: The company received a deficiency notice from Nasdaq on May 11, 2026, regarding failure to maintain the minimum $1.00 closing bid price. The company has until November 9, 2026, to regain compliance or risk delisting.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to the accounting for significant and complex transactions. Remediation efforts are ongoing, but controls were deemed ineffective as of June 30, 2026.
Investor Verification Checklist
- Verify the timeline and terms of the May 2026 Securities Purchase Agreement and the status of outstanding pre-funded warrants.
- Monitor the company's progress in regaining compliance with Nasdaq's minimum bid price requirement to avoid delisting.
- Review the status of remediation efforts for the material weakness in internal controls over financial reporting.
- Assess the sufficiency of the $53.4 million cash runway against the projected burn rate for ongoing clinical trials (RT-114) and manufacturing scale-up.
- Confirm the recognition criteria and future milestone potential associated with the Chugai Collaboration Agreement.